48 annotations
We exclude acquisition-related depreciation and amortization expense as they have no direct correlation to the cost of operating our business on an ongoing basis
(No comment added)
10-K/A
2022 FY
5 Sep 23
reclassified to interest expense, net, when the underlying transaction has an impact on earnings
(No comment added)
10-K/A
2022 FY
5 Sep 23
The Company’s backlog represents installment billings for periods beyond the current billing cycle. The majority of the Company’s noncurrent remaining performance obligations will be recognized in the next 13 to 36 month
(No comment added)
10-Q
2021 Q3
24 Aug 23
Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes unearned revenue and unbilled amounts that will be recognized as revenue in future periods
(No comment added)
10-Q
2021 Q3
24 Aug 23
unearned revenue and unbilled amounts that will be invoiced and recognized as revenue in future periods
(No comment added)
10-Q
2023 Q2
23 Aug 23
hat review identified up to $8.8 million of potential liability to states in which definitive may have been required to collect sales tax from customers
(No comment added)
Transcript
2023 Q2
22 Aug 23
Definitive HealthCare Corp. is taxed as a corporation and is subject to U.S. federal, state, and local income taxes with respect to its allocable share of any taxable income or loss of Definitive OpCo, as well as any such taxes on stand-alone income or loss generated by the Company. HSE, Monocl, AW and subsidiaries are taxed as corporations and are subject to U.S. federal, state, and local income taxes
(No comment added)
10-K/A
2022 FY
22 Aug 23
As a partnership, Definitive OpCo is generally not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by Definitive OpCo is passed through to and included in the taxable income or loss of its members, including Definitive Healthcare Corp
(No comment added)
10-K/A
2022 FY
22 Aug 23
Under the TRA, the Company generally will be required to pay certain pre-IPO owners 85% of the amount of cash savings, if any, in U.S. federal, state, or local tax that the Company actually realize
(No comment added)
10-K/A
2022 FY
22 Aug 23
Under the Tax Receivable Agreement, we are required to make cash payments to the TRA Parties equal to 85% of the tax benefits, if any, that Definitive Healthcare Corp. actually realizes
TRA
10-K/A
2022 FY
22 Aug 23
Costs capitalized related to new revenue contracts are amortized on a straight-line basis over four years, which reflects the average period of benefit, including expected contract renewals. When determining the period of benefit, the Company primarily considered its initial estimated customer life, the technological life of the subscription license, as well as an estimated customer relationship period. Costs capitalized related to renewal contracts are amortized on a straight-line basis over two years, which reflects the average renewal period. Renewal contracts with a term of one year or less are expensed.The capitalized amounts are recoverable through future revenue streams under all non-cancellable customer contracts. Amortization of capitalized costs to obtain revenue contracts is included in sales and marketing expense in the accompanying consolidated statements of operations. There were no impairments of these costs in the years ended December 31, 2022, 2021 or 2020
Deferred contract cost accounting
10-K/A
2022 FY
22 Aug 23
I think if you think about your Q3 and Q4 forecast, which we hope hopefully provided. And I think the right jumping off point is to roughly annualize the expected revenue run rate in Q4. More simple and direct. That's an approximation of ARR
USE FOR MODEL
Transcript
2023 Q2
20 Aug 23
And sometimes you lose a few of those. I don't think there's been an uptick in those per se, but certainly in a world where value really matters and is getting scrutinized
(No comment added)
Transcript
2023 Q2
20 Aug 23
So a lot of those deals end up taking longer than we want if we get them
(No comment added)
Transcript
2023 Q2
20 Aug 23
mean those are places that are cutting costs and they're looking at over dollar and they're pushing budgets out and their making higher approval levels
(No comment added)
Transcript
2023 Q2
20 Aug 23
If you go back 1.5 years, we have virtually zero of those
(No comment added)
Transcript
2023 Q2
20 Aug 23
pure financial distress
(No comment added)
Transcript
2023 Q2
20 Aug 23
we hope that our overall pricing would continue to go up by several percentage points each year that hasn't got
(No comment added)
Transcript
2023 Q2
20 Aug 23
So that's the hope. And I think if I look through our pipeline of deals, obviously, a lot of them are early stage, but they're out there
(No comment added)
Transcript
2023 Q2
20 Aug 23
And that creates a lot of revenue synergies and usually cost synergies.
(No comment added)
Transcript
2023 Q2
20 Aug 23